Efonidipine

Efonidipine

Systematic (IUPAC) name
2-(phenyl-(phenylmethyl)amino)ethyl 5-(5,5-dimethyl-2-oxo-1,3-dioxa-2λ5-phosphacyclohex-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate
Clinical data
Trade names	Landel (ランデル)
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
Legal status	℞ (Prescription only)
Identifiers
CAS Number	111011-63-3
ATC code	none
PubChem	CID 119171
ChemSpider	106463
UNII	40ZTP2T37Q
ChEMBL	CHEMBL2074922
Chemical data
Formula	C34H38N3O7P
Molar mass	631.65 g/mol
SMILES O=P1(OCC(CO1)(C)C)C/4=C(/N\C(=C(\C(=O)OCCN(c2ccccc2)Cc3ccccc3)C\4c5cccc([N+]([O-])=O)c5)C)C
InChI InChI=1S/C34H38N3O7P/c1-24-30(33(38)42-19-18-36(28-15-9-6-10-16-28)21-26-12-7-5-8-13-26)31(27-14-11-17-29(20-27)37(39)40)32(25(2)35-24)45(41)43-22-34(3,4)23-44-45/h5-17,20,31,35H,18-19,21-23H2,1-4H3 Key:NSVFSAJIGAJDMR-UHFFFAOYSA-N
(what is this?)  (verify)

Efonidipine (INN) is a dihydropyridine calcium channel blocker marketed by Shionogi & Co. of Japan. It was launched in 1995, under the brand name Landel (ランデル). The drug blocks both T-type and L-type calcium channels.^[1]

It has also been studied in atherosclerosis^[2] and acute renal failure.^[3]

References

1. Tanaka H, Shigenobu K (2002). "Efonidipine hydrochloride: a dual blocker of L- and T-type Ca²⁺ channels". Cardiovasc. Drug Rev. 20 (1): 81–92. PMID 12070536.
2. Toyoda K, Kitahara M, Yamashita T; et al. (May 1994). "[Effect of efonidipine hydrochloride (NZ-105), a new dihydropyridine calcium antagonist, on the experimental atherosclerosis in cholesterol-fed rabbits]". Nippon Yakurigaku Zasshi (in Japanese) 103 (5): 231–9. PMID 8188119.
3. Shudo C, Masuda Y, Sugita H, Tanaka S, Tomita K (November 1994). "Effects of efonidipine hydrochloride (NZ-105), a new calcium antagonist, against acute renal failure in rats". Gen. Pharmacol. 25 (7): 1451–8. PMID 7896060.

• (Japanese) Landel ランデル (PDF) Shionogi & Co. April 2005.